Fenwick represented Metagenomi, a genetic medicines company with a versatile portfolio of next-generation, in its strategic collaboration and licensing agreement with Affini-T Therapeutics, a biotechnology company unlocking the power of T cells against oncogenic driver mutations. The partnership will leverage Metagenomi’s proprietary gene editing systems to complement Affini-T’s state-of-the-art TCR discovery and synthetic biology platforms to generate groundbreaking cell therapy products.
Under the terms of the agreement, Metagenomi will be entitled to receive tiered payments for each optioned cancer target plus additional milestone and royalty payments. More information about the collaboration can be obtained from the announcement.
The Fenwick transaction team was led by life sciences partners Jake Handy and Matt Rossiter, and included corporate partner Jonathan Sagot and associate Joon Hwan Kim, and tax partner Julia Ushakova-Stein.